Test Price
2,800 AED✅ Home Collection Available
AGL Gene Glycogen Storage Disease Type 3 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين AGL لمرض تخزين الجليكوجين من النوع الثالث بتقنية التسلسل الجيني الشامل في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي لعام 2026
Executive Summary & Trust Signals
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved through ISO 9001:2015 accredited NGS processing with orthogonal Sanger confirmation of all clinically significant variants.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO-Certified Cold-Chain transport covering all seven emirates with temperature-controlled phlebotomy kits.
- VIP Mobile Phlebotomy: DHA-licensed phlebotomists dispatched to your location between 8 AM and 11 PM daily.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with a qualified genetic counselor to interpret results within the context of your family pedigree and clinical presentation.
- Insurance Support: Direct Billing Verification via WhatsApp at +971 54 548 8731. Pre-authorization assistance available.
الملخص التنفيذي وإشارات الثقة
- ضمان الدقة: حساسية تشخيصية تبلغ 99.9% من خلال معالجة التسلسل الجيني المعتمدة وفق معيار ISO 9001:2015 مع تأكيد الطفرات الهامة سريرياً بتقنية سانجر المتعامدة.
- الخدمات اللوجستية المتميزة: خدمة جمع العينات منزلية متميزة عبر نقل مبرد معتمد بمعايير الأيزو تغطي كافة الإمارات السبع باستخدام أدوات فصد معقمة ومتحكم بدرجة حرارتها.
- خدمة الفصد المتنقلة: أخصائيو فصد مرخصون من هيئة الصحة بدبي يصلون إلى موقعكم بين الثامنة صباحاً والحادية عشرة مساءً يومياً.
- الإرشاد السريري: استشارة وراثية هاتفية بعد الفحص مع مستشار وراثي مؤهل لتفسير النتائج ضمن سياق شجرة العائلة الوراثية والعرض السريري للمريض.
- دعم التأمين: التحقق المباشر من تغطية التأمين عبر تطبيق واتساب على الرقم +971 54 548 8731. تتوفر المساعدة في الحصول على الموافقة المسبقة.
Overview
The AGL Gene Glycogen Storage Disease Type 3 Genetic Test is a comprehensive next-generation sequencing assay that analyzes the full coding region of the AGL (amylo-alpha-1,6-glucosidase, 4-alpha-glucanotransferase) gene to identify pathogenic variants responsible for Glycogen Storage Disease Type III (GSD III), also known as Cori Disease or Forbes Disease. This autosomal recessive inborn error of metabolism impairs glycogen debranching enzyme activity, leading to abnormal glycogen accumulation in the liver, skeletal muscle, and cardiac tissue. يكشف هذا التحليل الجيني الشامل عن الطفرات المسببة لمرض تخزين الجليكوجين من النوع الثالث، مما يتيح التشخيص الدقيق والتدخل العلاجي المبكر للمرضى وعائلاتهم في دولة الإمارات.
| Parameter | Our Test (NGS – AGL Full Gene) | Closest Alternative (Sanger Single-Exon) |
|---|---|---|
| Precision / Coverage | Full AGL gene: all 33 coding exons, intron-exon boundaries, and 5'/3' UTR regions | Targeted single-exon or hotspot analysis only; may miss deep intronic or novel variants |
| Methodology | Illumina NovaSeq X Plus platform with 300x mean depth; variant confirmation via orthogonal Sanger sequencing | Capillary electrophoresis-based Sanger sequencing; lower throughput and limited multiplexing |
| Turnaround Time | 21 to 28 calendar days with interim verbal report at Day 14 | 6 to 10 weeks per gene segment; sequential testing required for full coverage |
| Clinical Utility | Definitive molecular diagnosis, carrier screening, prenatal counseling, and genotype-phenotype correlation | Preliminary screening; often requires reflex to broader NGS panel |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy — Senior Clinical Pathologist, DHA License No. 61713011
"A positive AGL gene variant confirms the molecular diagnosis of GSD Type III, but it must always be interpreted in tandem with biochemical enzyme assays and clinical phenotype. I strongly remind families that this test is a diagnostic tool and not a standalone verdict — please engage with your metabolic specialist and genetic counselor to fully understand the implications for dietary management, surveillance of hepatomegaly and cardiomyopathy, and reproductive planning. Every result carries a human story behind it, and we are here to guide you through each step with clinical empathy and precision."
⚠ Medication Advisory
Do not discontinue any prescribed medication or dietary regimen without consulting your treating physician. Patients with suspected or confirmed GSD Type III may be on medically prescribed cornstarch therapy, high-protein dietary protocols, or cardiac medications. Abrupt cessation can precipitate life-threatening hypoglycemia or metabolic decompensation, particularly in pediatric patients.
🛑 Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Do Not Proceed with Home Collection If):
- Patient is currently experiencing acute hypoglycemic episode (blood glucose < 3.3 mmol/L or 60 mg/dL).
- Patient has active febrile illness (>38.5°C) or uncontrolled seizure activity.
- Patient is under 48 hours post-blood transfusion; cell-free DNA contamination may confound results.
- Inability to provide informed consent (for minors, both parents or legal guardian must provide CDS Law 2026-compliant dual consent).
- Incomplete pre-test genetic counseling session or missing signed pedigree documentation.
Emergency Red Flags — Seek Immediate Medical Attention:
- Unexplained lethargy, confusion, or loss of consciousness (suspect severe hypoglycemia).
- Acute abdominal distension with right upper quadrant pain (suspect rapid hepatomegaly or hepatic adenoma).
- New-onset chest pain, palpitations, or dyspnea on exertion (suspect cardiomyopathy — echocardiogram indicated).
- Progressive proximal muscle weakness with elevated creatine kinase (CK > 1000 U/L).
- Failure to thrive or growth faltering in infants and toddlers with known GSD III.
This safety information is aligned with 2026 DHA Clinical Practice Guidelines and Federal Decree-Law No. 41 of 2024 (Art. 87). If any red flag symptom is present, proceed to the nearest emergency department or call 998 (UAE Ambulance).
Patient FAQ & Clinical Guidance
Q1: What exactly does the AGL gene NGS test detect, and how does it help my family?
Snippet: This test detects pathogenic single-nucleotide variants, small insertions/deletions, and copy-number variations across the entire AGL gene, enabling definitive molecular confirmation of Glycogen Storage Disease Type III.
By identifying the specific AGL mutations present in an affected individual, this genetic provides a conclusive molecular diagnosis that distinguishes GSD Type III from other glycogen storage disorders (such as GSD Type I or Type VI). This clarity allows your clinical team to tailor dietary management (high-protein, cornstarch-based regimens), initiate appropriate cardiac surveillance, and offer accurate carrier testing and prenatal diagnosis to at-risk family members.
بالعربية: يكشف هذا التحليل عن الطفرات الجينية المرضية في كامل جين AGL، مما يتيح التشخيص الجزيئي القاطع لمرض تخزين الجليكوجين من النوع الثالث وتوجيه خطة العلاج الغذائي والمراقبة القلبية للحالة.
Q2: What is the sample collection process, and is home collection available across all UAE emirates?
Snippet: A DHA-licensed phlebotomist collects 3-5 mL of whole blood in an EDTA tube at your home, which is then transported under ISO-certified cold-chain conditions to our central laboratory.
Home collection is available across all seven emirates — Abu Dhabi, Dubai, Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah — between 8:00 AM and 11:00 PM daily. The phlebotomist arrives with a complete temperature-monitored kit. For pediatric patients, a single drop of blood on an FTA card may be accepted as an alternative sample type, subject to prior laboratory approval. Extracted DNA samples from external laboratories are also accepted provided they meet our purity (A260/A280 ratio 1.8–2.0) and concentration (≥50 ng/µL) criteria.
بالعربية: تتوفر خدمة جمع العينات منزلياً في جميع إمارات الدولة السبع عبر أخصائيي فصد مرخصين من هيئة الصحة بدبي، مع نقل العينات وفق سلسلة تبريد معتمدة بمعايير الأيزو لضمان سلامة العينة.
Q3: How reliable are these results, and what quality controls do you use?
Snippet: Our laboratory employs a dual-platform validation protocol where all clinically significant NGS findings are orthogonally confirmed by Sanger sequencing, achieving 99.9% analytical sensitivity and specificity.
Every sequencing run includes internal quality metrics: mean target coverage ≥300x, Q30 score ≥90%, and uniformity ≥95%. External quality assurance is maintained through annual participation in the College of American Pathologists (CAP) NGS proficiency testing and the European Molecular Genetics Quality Network (EMQN) external quality assessment scheme for inherited metabolic disorders. The laboratory operates under ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and is fully compliant with Federal Decree-Law No. 41 of 2024. Variant classification follows ACMG/AMP 2026 consensus guidelines.
بالعربية: يلتزم مختبرنا ببروتوكول تحقق مزدوج حيث يتم تأكيد جميع نتائج التسلسل الجيني ذات الأهمية السريرية بتقنية سانجر المتعامدة، محققاً حساسية ونوعية تحليلية تبلغ 99.9% وفق إرشادات الكلية الأمريكية لعلم الأمراض والشبكة الأوروبية لجودة الوراثة الجزيئية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians